In this upbeat interview, CEO Sara Barrington of 

Verici DX – a next generation medical diagnostics firm focusing on the global kidney transplant market - takes me through:

00:00 Verici's £6.35m recent fund raise and planned use of proceeds.

02:45 Commercialisation of its flagship blood test Tutivia.

09:20 $300m total addressable market for Tutivia

21:35 Relationship with Thermo Fisher Scientific (re pre-graft Clarava/PTRA test)

24:15 Update on 3rd diagnostic (Protega) and closing remarks